GBA1 in Parkinson’s disease: past, present and future

Clicks: 18
ID: 329084
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #99 of 406 articles by views in Brain research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 406 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract GBA1 variants represent some of the most important genetic risk factors for Parkinson’s disease (PD), present in a substantial proportion of patients across populations. This review provides a comprehensive overview of the field, tracing the historical path from the first description of Gaucher disease (GD) in 1882 to the recognition of GBA1 as a key contributor to PD risk, and highlighting major scientific and translational milestones along the way. We summarize current understanding of the biological mechanisms linking GBA1 to PD, including both loss-of-function and gain-of-function hypotheses, and discuss how reduced glucocerebrosidase (GCase) activity may lead to α-synuclein accumulation and neurodegeneration. Remaining gaps in knowledge, especially regarding downstream lipidomic effects and cell-type-specific mechanisms, are emphasized as key priorities for future research. This review also examines clinical and translational advances, including the development of GCase-targeted therapies such as small molecules, chaperones, substrate reduction therapies, and gene-based approaches. We discuss outcomes from recent and ongoing clinical trials, highlighting both promising strategies and notable failures that inform our evolving understanding of disease biology. In addition, we address the heterogeneity of PD and the importance of stratifying patients based on genetic background. Finally, we outline critical challenges and future directions, including the need for precision medicine approaches based on variant-specific mechanisms, improved biomarkers to define true GBA1-associated PD, and optimized clinical trial design. We propose that coordinated, open-science efforts and large-scale collaborative frameworks will be essential to accelerate discovery and translate mechanistic insights into effective disease-modifying therapies.
Reference Key
openalex_W7213547627 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ziv Gan‐Or
Journal Brain research
Year 2026
DOI
10.1093/brain/awag322
URL
https://doi.org/10.1093/brain/awag322
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.